Tricuspid Version of Abbott’s MitraClip Improves Short-Term Outcomes In TRILUMINATE

Early results of the TRILUMINATE trial presented at the EuroPCR conference will support a CE mark for a version of MitraClip adapted to reduce tricuspid valve regurgitation.

BEIJING, CHINA- JULY 15, 2017: Abbott sign; Abbott Laboratories, founded in 1888, is a health care company that serves worldwide. It has more than 20 billon USD in revenue last year. - Image
• Source: shutterstock.com

Initial results from the TRILUMINATE trial show Abbott Laboratories Inc.’s transcatheter tricuspid valve repair (TTVR) system can significantly reduce tricuspid regurgitation and improve heart failure symptoms.

Tricuspid regurgitation, a backward flow of blood from the heart’s right ventricle through the tricuspid valve into the right atrium, can eventually cause right-heart failure. About 3% of people over...

More from Clinical Trials

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from R&D